Medical drug program updates
You can refer to the chart below to review changes and updates related to CarePartners of Connecticut's prior authorization and coverage program for medical drugs.
New prior authorization programs
| ||
Drug/MNG
| Plan and additional information
| Effective date
|
| Prior authorization is now required for Kebilidi (J3590), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase deficiency. Our coverage criteria are aligned with MassHealth’s, as is the case for all gene therapies. | 10/1/2025
|
| The ophthalmology drug Encelto (J3403) is covered with prior authorization.
| 10/1/2025
|